Loading…
Adverse effects of antiretroviral therapy for HIV infection
Long-term remission of HIV-1 disease can be readily achieved by combinations of antiretroviral agents. The suppression of plasma viral loads to less than the limit of quantification of the most sensitive commercially available assays (i.e., less than 50 copies/mL) and the coincident improvement in C...
Saved in:
Published in: | Canadian Medical Association journal 2004-01, Vol.170 (2), p.229-238 |
---|---|
Main Authors: | , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | |
container_end_page | 238 |
container_issue | 2 |
container_start_page | 229 |
container_title | Canadian Medical Association journal |
container_volume | 170 |
creator | Montessori, Valentina Press, Natasha Harris, Marianne Akagi, Linda Montaner, Julio S.G |
description | Long-term remission of HIV-1 disease can be readily achieved by combinations of antiretroviral agents. The suppression of plasma viral loads to less than the limit of quantification of the most sensitive commercially available assays (i.e., less than 50 copies/mL) and the coincident improvement in CD4 T cell counts is associated with resolution of established opportunistic infections and a decrease in the risk of new opportunistic infections. However, prolonged treatment with combination regimens can be difficult to sustain because of problems with adherence and toxic effects. All antiretroviral drugs can have both short-term and long-term adverse events. The risk of specific side effects varies from drug to drug, from drug class to drug class, and from patient to patient. A better understanding of the adverse effects of antiretroviral agents is of interest not only for HIV specialists as they try to optimize therapy, but also for other physicians who care for HIV-positive patients. |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_315530</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>544099171</sourcerecordid><originalsourceid>FETCH-LOGICAL-h350t-8c9e968c4ee351cad2815ea63606fa1938da59b701be6160f88c90d34fd50a883</originalsourceid><addsrcrecordid>eNpdkF9LwzAUxYMobk6_ghQffCskTdKmiA9jqBsMfFFfQ9berBltM5N2Zd_eDOffpwv3_s69554TNCZMiDihSX6KxhhjETOG8xG68H6Dcehjdo5GhGWUMSrG6G5a7sB5iEBrKDofWR2ptjMOOmd3xqk66ipwaruPtHXRfPEWmfZAGtteojOtag9XxzpBr48PL7N5vHx-Wsymy7iiHHexKHLIU1EwAMpJocpEEA4qpSlOtSI5FaXi-SrDZAUpSbEWQYFLynTJsRKCTtD9595tv2qgLKDtgi-5daZRbi-tMvLvpDWVXNudpIRzioP-9qh39r0H38nG-ALqWrVgey9JljOeJIdDN__Aje1dG36TITcRrKYH6Pq3m28bX5n-nKvMuhpCktI3qq4DTuQwDCTDMpFJktMPdIyBGg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>204819368</pqid></control><display><type>article</type><title>Adverse effects of antiretroviral therapy for HIV infection</title><source>PubMed Central</source><creator>Montessori, Valentina ; Press, Natasha ; Harris, Marianne ; Akagi, Linda ; Montaner, Julio S.G</creator><creatorcontrib>Montessori, Valentina ; Press, Natasha ; Harris, Marianne ; Akagi, Linda ; Montaner, Julio S.G</creatorcontrib><description>Long-term remission of HIV-1 disease can be readily achieved by combinations of antiretroviral agents. The suppression of plasma viral loads to less than the limit of quantification of the most sensitive commercially available assays (i.e., less than 50 copies/mL) and the coincident improvement in CD4 T cell counts is associated with resolution of established opportunistic infections and a decrease in the risk of new opportunistic infections. However, prolonged treatment with combination regimens can be difficult to sustain because of problems with adherence and toxic effects. All antiretroviral drugs can have both short-term and long-term adverse events. The risk of specific side effects varies from drug to drug, from drug class to drug class, and from patient to patient. A better understanding of the adverse effects of antiretroviral agents is of interest not only for HIV specialists as they try to optimize therapy, but also for other physicians who care for HIV-positive patients.</description><identifier>ISSN: 0008-4409</identifier><identifier>ISSN: 0820-3946</identifier><identifier>EISSN: 1488-2329</identifier><identifier>PMID: 14734438</identifier><identifier>CODEN: CMAJAX</identifier><language>eng</language><publisher>Canada: Can Med Assoc</publisher><subject>Anti-HIV Agents - adverse effects ; Anti-HIV Agents - therapeutic use ; Antiretroviral Therapy, Highly Active - adverse effects ; Antiretroviral Therapy, Highly Active - methods ; Chemical and Drug Induced Liver Injury ; Drug Therapy, Combination ; Drugs ; Female ; Follow-Up Studies ; HIV ; HIV Infections - diagnosis ; HIV Infections - drug therapy ; HIV Infections - mortality ; Human immunodeficiency virus ; Humans ; Hyperglycemia - chemically induced ; Hyperglycemia - epidemiology ; Hyperlipidemias - chemically induced ; Hyperlipidemias - epidemiology ; Incidence ; Lipodystrophy - chemically induced ; Lipodystrophy - epidemiology ; Liver Diseases - epidemiology ; Male ; Osteonecrosis - chemically induced ; Osteonecrosis - epidemiology ; Physiological aspects ; Randomized Controlled Trials as Topic ; Review ; Risk Assessment ; Skin Diseases - chemically induced ; Skin Diseases - epidemiology ; Survival Analysis ; Treatment</subject><ispartof>Canadian Medical Association journal, 2004-01, Vol.170 (2), p.229-238</ispartof><rights>Copyright Canadian Medical Association Jan 20, 2004</rights><rights>2004 Canadian Medical Association or its licensors</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC315530/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC315530/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14734438$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Montessori, Valentina</creatorcontrib><creatorcontrib>Press, Natasha</creatorcontrib><creatorcontrib>Harris, Marianne</creatorcontrib><creatorcontrib>Akagi, Linda</creatorcontrib><creatorcontrib>Montaner, Julio S.G</creatorcontrib><title>Adverse effects of antiretroviral therapy for HIV infection</title><title>Canadian Medical Association journal</title><addtitle>CMAJ</addtitle><description>Long-term remission of HIV-1 disease can be readily achieved by combinations of antiretroviral agents. The suppression of plasma viral loads to less than the limit of quantification of the most sensitive commercially available assays (i.e., less than 50 copies/mL) and the coincident improvement in CD4 T cell counts is associated with resolution of established opportunistic infections and a decrease in the risk of new opportunistic infections. However, prolonged treatment with combination regimens can be difficult to sustain because of problems with adherence and toxic effects. All antiretroviral drugs can have both short-term and long-term adverse events. The risk of specific side effects varies from drug to drug, from drug class to drug class, and from patient to patient. A better understanding of the adverse effects of antiretroviral agents is of interest not only for HIV specialists as they try to optimize therapy, but also for other physicians who care for HIV-positive patients.</description><subject>Anti-HIV Agents - adverse effects</subject><subject>Anti-HIV Agents - therapeutic use</subject><subject>Antiretroviral Therapy, Highly Active - adverse effects</subject><subject>Antiretroviral Therapy, Highly Active - methods</subject><subject>Chemical and Drug Induced Liver Injury</subject><subject>Drug Therapy, Combination</subject><subject>Drugs</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>HIV</subject><subject>HIV Infections - diagnosis</subject><subject>HIV Infections - drug therapy</subject><subject>HIV Infections - mortality</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Hyperglycemia - chemically induced</subject><subject>Hyperglycemia - epidemiology</subject><subject>Hyperlipidemias - chemically induced</subject><subject>Hyperlipidemias - epidemiology</subject><subject>Incidence</subject><subject>Lipodystrophy - chemically induced</subject><subject>Lipodystrophy - epidemiology</subject><subject>Liver Diseases - epidemiology</subject><subject>Male</subject><subject>Osteonecrosis - chemically induced</subject><subject>Osteonecrosis - epidemiology</subject><subject>Physiological aspects</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Review</subject><subject>Risk Assessment</subject><subject>Skin Diseases - chemically induced</subject><subject>Skin Diseases - epidemiology</subject><subject>Survival Analysis</subject><subject>Treatment</subject><issn>0008-4409</issn><issn>0820-3946</issn><issn>1488-2329</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><recordid>eNpdkF9LwzAUxYMobk6_ghQffCskTdKmiA9jqBsMfFFfQ9berBltM5N2Zd_eDOffpwv3_s69554TNCZMiDihSX6KxhhjETOG8xG68H6Dcehjdo5GhGWUMSrG6G5a7sB5iEBrKDofWR2ptjMOOmd3xqk66ipwaruPtHXRfPEWmfZAGtteojOtag9XxzpBr48PL7N5vHx-Wsymy7iiHHexKHLIU1EwAMpJocpEEA4qpSlOtSI5FaXi-SrDZAUpSbEWQYFLynTJsRKCTtD9595tv2qgLKDtgi-5daZRbi-tMvLvpDWVXNudpIRzioP-9qh39r0H38nG-ALqWrVgey9JljOeJIdDN__Aje1dG36TITcRrKYH6Pq3m28bX5n-nKvMuhpCktI3qq4DTuQwDCTDMpFJktMPdIyBGg</recordid><startdate>20040120</startdate><enddate>20040120</enddate><creator>Montessori, Valentina</creator><creator>Press, Natasha</creator><creator>Harris, Marianne</creator><creator>Akagi, Linda</creator><creator>Montaner, Julio S.G</creator><general>Can Med Assoc</general><general>CMA Impact, Inc</general><general>Canadian Medical Association</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>4T-</scope><scope>4U-</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8FQ</scope><scope>8FV</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>ASE</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FPQ</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K6X</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M3G</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7T2</scope><scope>7U1</scope><scope>7U2</scope><scope>7U9</scope><scope>C1K</scope><scope>H94</scope><scope>5PM</scope></search><sort><creationdate>20040120</creationdate><title>Adverse effects of antiretroviral therapy for HIV infection</title><author>Montessori, Valentina ; Press, Natasha ; Harris, Marianne ; Akagi, Linda ; Montaner, Julio S.G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h350t-8c9e968c4ee351cad2815ea63606fa1938da59b701be6160f88c90d34fd50a883</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Anti-HIV Agents - adverse effects</topic><topic>Anti-HIV Agents - therapeutic use</topic><topic>Antiretroviral Therapy, Highly Active - adverse effects</topic><topic>Antiretroviral Therapy, Highly Active - methods</topic><topic>Chemical and Drug Induced Liver Injury</topic><topic>Drug Therapy, Combination</topic><topic>Drugs</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>HIV</topic><topic>HIV Infections - diagnosis</topic><topic>HIV Infections - drug therapy</topic><topic>HIV Infections - mortality</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Hyperglycemia - chemically induced</topic><topic>Hyperglycemia - epidemiology</topic><topic>Hyperlipidemias - chemically induced</topic><topic>Hyperlipidemias - epidemiology</topic><topic>Incidence</topic><topic>Lipodystrophy - chemically induced</topic><topic>Lipodystrophy - epidemiology</topic><topic>Liver Diseases - epidemiology</topic><topic>Male</topic><topic>Osteonecrosis - chemically induced</topic><topic>Osteonecrosis - epidemiology</topic><topic>Physiological aspects</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Review</topic><topic>Risk Assessment</topic><topic>Skin Diseases - chemically induced</topic><topic>Skin Diseases - epidemiology</topic><topic>Survival Analysis</topic><topic>Treatment</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Montessori, Valentina</creatorcontrib><creatorcontrib>Press, Natasha</creatorcontrib><creatorcontrib>Harris, Marianne</creatorcontrib><creatorcontrib>Akagi, Linda</creatorcontrib><creatorcontrib>Montaner, Julio S.G</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Docstoc</collection><collection>University Readers</collection><collection>Proquest Nursing & Allied Health Source</collection><collection>Health & Medical Collection (Proquest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Canadian Business & Current Affairs Database</collection><collection>Canadian Business & Current Affairs Database (Alumni Edition)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>British Nursing Database</collection><collection>British Nursing Index</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>British Nursing Index</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest Healthcare Administration Database</collection><collection>PML(ProQuest Medical Library)</collection><collection>Psychology Database (ProQuest)</collection><collection>ProQuest research library</collection><collection>ProQuest Science Journals</collection><collection>CBCA Reference & Current Events</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Risk Abstracts</collection><collection>Safety Science and Risk</collection><collection>Virology and AIDS Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Canadian Medical Association journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Montessori, Valentina</au><au>Press, Natasha</au><au>Harris, Marianne</au><au>Akagi, Linda</au><au>Montaner, Julio S.G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Adverse effects of antiretroviral therapy for HIV infection</atitle><jtitle>Canadian Medical Association journal</jtitle><addtitle>CMAJ</addtitle><date>2004-01-20</date><risdate>2004</risdate><volume>170</volume><issue>2</issue><spage>229</spage><epage>238</epage><pages>229-238</pages><issn>0008-4409</issn><issn>0820-3946</issn><eissn>1488-2329</eissn><coden>CMAJAX</coden><abstract>Long-term remission of HIV-1 disease can be readily achieved by combinations of antiretroviral agents. The suppression of plasma viral loads to less than the limit of quantification of the most sensitive commercially available assays (i.e., less than 50 copies/mL) and the coincident improvement in CD4 T cell counts is associated with resolution of established opportunistic infections and a decrease in the risk of new opportunistic infections. However, prolonged treatment with combination regimens can be difficult to sustain because of problems with adherence and toxic effects. All antiretroviral drugs can have both short-term and long-term adverse events. The risk of specific side effects varies from drug to drug, from drug class to drug class, and from patient to patient. A better understanding of the adverse effects of antiretroviral agents is of interest not only for HIV specialists as they try to optimize therapy, but also for other physicians who care for HIV-positive patients.</abstract><cop>Canada</cop><pub>Can Med Assoc</pub><pmid>14734438</pmid><tpages>10</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0008-4409 |
ispartof | Canadian Medical Association journal, 2004-01, Vol.170 (2), p.229-238 |
issn | 0008-4409 0820-3946 1488-2329 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_315530 |
source | PubMed Central |
subjects | Anti-HIV Agents - adverse effects Anti-HIV Agents - therapeutic use Antiretroviral Therapy, Highly Active - adverse effects Antiretroviral Therapy, Highly Active - methods Chemical and Drug Induced Liver Injury Drug Therapy, Combination Drugs Female Follow-Up Studies HIV HIV Infections - diagnosis HIV Infections - drug therapy HIV Infections - mortality Human immunodeficiency virus Humans Hyperglycemia - chemically induced Hyperglycemia - epidemiology Hyperlipidemias - chemically induced Hyperlipidemias - epidemiology Incidence Lipodystrophy - chemically induced Lipodystrophy - epidemiology Liver Diseases - epidemiology Male Osteonecrosis - chemically induced Osteonecrosis - epidemiology Physiological aspects Randomized Controlled Trials as Topic Review Risk Assessment Skin Diseases - chemically induced Skin Diseases - epidemiology Survival Analysis Treatment |
title | Adverse effects of antiretroviral therapy for HIV infection |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T04%3A45%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Adverse%20effects%20of%20antiretroviral%20therapy%20for%20HIV%20infection&rft.jtitle=Canadian%20Medical%20Association%20journal&rft.au=Montessori,%20Valentina&rft.date=2004-01-20&rft.volume=170&rft.issue=2&rft.spage=229&rft.epage=238&rft.pages=229-238&rft.issn=0008-4409&rft.eissn=1488-2329&rft.coden=CMAJAX&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E544099171%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-h350t-8c9e968c4ee351cad2815ea63606fa1938da59b701be6160f88c90d34fd50a883%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=204819368&rft_id=info:pmid/14734438&rfr_iscdi=true |